Company Spotlight

Top 6 Companies in the Phenylketonuria Treatment Market

Top 6 Companies in the Phenylketonuria Treatment Market

Insights

BioMarin Pharmaceutical Inc., PTC Therapeutics, Inc., Synologic Inc., SOM Innovation Biotech S.A., Codexis, Inc., and Homology Medicines, Inc. are some of the leading players in the phenylketonuria treatment market.

The phenylketonuria treatment market was valued at USD 594.56 million in 2023. The market is expected to grow at a CAGR of 10% during the forecast period of 2024-2032. The market is driven by the rising incidence of phenylketonuria and advancements in treatment options across the 8 major markets.

Phenylketonuria is a rare genetic disorder that is triggered by a lack of the enzyme phenylalanine hydroxylase, resulting in an accumulation of phenylalanine in the body. If not addressed, this could lead to delay in development and impairments in cognition. Management includes following a diet low in protein and consistently checking phenylalanine levels. Early detection and proper care are essential to avoid harm to the brain. Possible treatments involve medication and gene therapy which is currently being explored to address the underlying genetic cause of the disease. Even though phenylketonuria can be identified through screenings of newborns, adhering to the diet may pose difficulties. Receiving assistance from medical professionals and advocacy organizations is crucial for managing the intricacies of the illness.

The market is influenced by the increasing occurrence of phenylketonuria. The National Phenylketonuria Alliance reports that by 2024, it is projected that there will be around 13,500 individuals with phenylketonuria in the United States, leading to a growing demand for improved management strategies such as tailored diets and innovative medications. The increasing availability of enzyme replacement therapies and gene therapy is leading to a higher demand for non-dietary treatments, which is in turn broadening the market for specialized medical foods and therapies for individuals with phenylketonuria.

In October 2023, POA Pharma launched phenylketonuria easy microtabs plus in Germany and the Nordic region, marking their entry into the market for inborn metabolic diseases. Continuous efforts in research and development seek to improve treatment options for phenylketonuria and are expected to boost the phenylketonuria treatment market value in the coming years.

Let’s explore the profile of top companies leading the phenylketonuria treatment market in 2024.

1.    BioMarin Pharmaceutical Inc.

Headquarters California, United States
Establishment 1997
Website https://www.biomarin.com/

BioMarin Pharmaceutical, headquartered in California, creates cutting-edge drugs for rare genetic disorders. Their palynziq product assists adult individuals with phenylketonuria by decreasing blood phenylalanine levels. Palynziq is a man-made enzyme modified with PEG designed to address the root cause of phenylketonuria by breaking down phenylalanine. It is utilized when conventional management methods fail, and blood phenylalanine levels are not regulated.

2.    PTC Therapeutics, Inc.

Headquarters New Jersey, United States
Establishment 1998
Website https://www.ptcbio.com/

PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. In October 2024, the company received FDA acceptance for filing a new drug application for sapropterin, aimed at treating phenylketonuria patients by enhancing the activity of the PAH enzyme

3.    Synlogic Inc.

Headquarters Massachusetts, United States
Establishment 2014
Website https://www.synlogictx.com/

Synlogic is actively involved in the phenylketonuria treatment market through the development of SYNB1618, an investigational oral therapeutic candidate designed to treat phenylketonuria. The company's approach involves a genetically modified bacterium, E. coli Nissle, which functions as a probiotic to break down phenylalanine, the amino acid that accumulates to toxic levels in phenylketonuria patients. By using this dual mechanism of degradation through enzymes phenylalanine ammonia-lyase (PAL) and L-amino acid deaminase (LAAD), the treatment aims to lower phenylalanine levels both from dietary intake and via recycling processes between the gut and the bloodstream.

4.    SOM Innovation Biotech S.A.

Headquarters Barcelona, Spain
Establishment 2009
Website https://sombiotech.com/

SOM Innovation Biotech is a private pharmaceutical company focused on the accelerated discovery and development of therapies for orphan diseases through a proprietary artificial intelligence-based drug discovery technology. The company's investigational candidate SOM1311 is a small molecule pharmacological chaperone of phenylalanine hydroxylase, designed for the treatment of phenylketonuria. The drug shows an improved response rate compared to the current standard of care.

5.    Codexis, Inc.

Headquarters California, United States
Establishment 2002
Website https://www.codexis.com/

Codexis, Inc. is a company specializing in protein engineering, creating enzymes for industries such as pharmaceuticals, food, and medical applications. CDX-6114, an enzyme treatment for phenylketonuria, a condition where individuals are unable to metabolize phenylalanine, is one of the key products of this company. The promising results from the Phase 1a trial with healthy volunteers demonstrate its potential for future treatments in the phenylketonuria market, establishing Codexis’s position in enzyme-based therapies.

6.    Homology Medicines, Inc.

Headquarters Massachusetts, United States
Establishment 2015
Website https://www.q32bio.com/

Homology Medicines is a genetic medicines company that specializes in rare diseases and aims to treat the underlying cause of the illness. In July 2023, they announced encouraging initial clinical results for their gene editing therapy for classical phenylketonuria. Further, in March 2024, Q32 Bio Inc., a company focused on immune therapies, finalized its merger with Homology Medicines and a simultaneous private investment, creating a new company called Q32 Bio.

How to Purchase a Report

Website

To place an order through our website, select the license type mentioned on the report details page. Click on the ‘Buy Now’ button and fill in your details. Select your preferred mode of payment after which you will be redirected to the selected payment gateway. Follow the steps and proceed to checkout.

www.expertmarketresearch.com

Email

Enlisting all your requirements and queries along with details that include billing and delivery address and the preferred payment mode. Our customer service representative will revert to you within 24 hours.

[email protected]

Telephone

To place an order through telephone, call our sales team on the following numbers and our customer service representative will help you regarding the same.

+61 291 889 415

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124